Author: vincenzo

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells: Cell Reports Medicine
— Read on www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2

Yet another study confirming both B and T cell long lasting and stable immunity in Covid-19 recovered patients. Those who have had Covid-19 DO NOT NEED the vaccine. Yet in many countries they are being threatened with #GreenPass, which can only be kept “Green” with regular doses of vaccine.

This randomized clinical trial measured inhaled and exhaled carbon dioxide in children with and without face masks.
— Read on jamanetwork.com/journals/jamapediatrics/fullarticle/2781743

To have covered up the knowledge for four decades that viruses could potentially be treated by antimicrobials required extensive effort
— Read on www.palmerfoundation.com.au/the-treatment-of-viral-diseases-has-the-truth-been-suppressed-for-decades/

The COVID-19 pandemic has revealed a range of disease phenotypes in infected patients with asymptomatic, mild, or severe clinical outcomes, but the mechanisms that determine such variable outcomes remain unresolved. In this study, we identified immunodominant CD8 T-cell epitopes in the spike antigen using a novel TCR-binding algorithm. The predicted epitopes induced robust T-cell activation in unexposed donors demonstrating pre-existing CD4 and CD8 T-cell immunity to SARS-CoV-2 antigen. The T-cell reactivity to the predicted epitopes was higher than the Spike-S1 and S2 peptide pools in the unexposed donors. A key finding of our study is that pre-existing T-cell immunity to SARS-CoV-2 is contributed by TCRs that recognize common viral antigens such as Influenza and CMV, even though the viral epitopes lack sequence identity to the SARS-CoV-2 epitopes. This finding is in contrast to multiple published studies in which pre-existing T-cell immunity is suggested to arise from shared epitopes between SARS-CoV-2 and other common cold-causing coronaviruses. However, our findings suggest that SARS-CoV-2 reactive T-cells are likely to be present in many individuals because of prior exposure to flu and CMV viruses.
— Read on www.nature.com/articles/s41598-021-92521-4

The inventor of the mRNA vaccine technology that went into some COVID vaccines told “Tucker Carlson Tonight” on Wednesday that YouTube deleted a video in which he discussed his concerns and findings.
— Read on www.foxnews.com/media/tucker-carlson-mrna-vaccine-inventor

A narrowly tailored single vaccine allows RNA viruses to mutate and evolve resistance, while the multi-drug cocktail prevents this. By simply adding Ivermectin to the vaccines, the world could quickly overcome the problem of variants in a matter of weeks.
— Read on www.thedesertreview.com/content/tncms/live/

“We made a mistake”. In a recent interview with journalist Alex Pierson, Professor Byram Bridle, a specialist in viral immunology, says this new research and work has led him to make important discoveries about the virus and in particular the Spike protein. This protein is the one that has been the subject of much work, particularly on messenger RNA vaccines.
— Read on www.francesoir.fr/societe-sante/nous-avons-fait-une-erreur-la-proteine-spike-est-elle-meme-toxique-et-dangereuse-pour

JCI Insight – A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2
— Read on insight.jci.org/articles/view/146316

The “new virus”. I predicted pre existing immunity to it ages ago. Both B and T cells immunity, even cross reactive, is now a fact. The mass vaccination programme makes no sense, unless other reasons for it are taken into account.

Ivermectin for Prevention and Treatment of COVID-19 Infectio… : American Journal of Therapeutics
— Read on journals.lww.com/americantherapeutics/Abstract/9000/Ivermectin_for_Prevention_and_Treatment_of.98040.aspx

Ivermectin works. It’s been working since April 2020. Thanks for letting people die needlessly.